In a nutshell This study aimed to investigate if venetoclax was safe and effective in older patients with relapsed/refractory chronic lymphocytic leukemia outside of clinical trials. This study concluded that venetoclax is safe and effective in these patients. Some background Chronic lymphocytic leukemia (CLL) is commonly diagnosed in older people....
Read MoreCurrent treatment status-Undergoing active treatment-Partial response Posts on Medivizor
The effects of blinatumomab in patients with relapsed or unresponsive acute lymphoblastic leukemia in outside of clinical trials
In a nutshell The study evaluated the safety and effectiveness of blinatumomab (Blincyto) in patients with relapsed or unresponsive B-acute lymphoblastic leukemia (B-ALL) outside of clinical trials. The authors found that blinatumomab was safe and effective to treat such patients in real-world medical practice. Some background Relapsed...
Read MoreEvaluating the R-BAC regimen for patients with MCL that stops responding to TKI therapy
In a nutshell This study evaluated the outcomes of the R-BAC (rituximab, bendamustine, cytarabine) regimen for patients with relapsed or unresponsive mantle cell lymphoma (MCL). This study concluded that R-BAC was effective for these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL). After initial...
Read MoreEvaluating BEGEV chemotherapy before a stem cell transplant for hard-to-treat Hodgkin lymphoma
In a nutshell This study evaluated the effectiveness of BEGEV chemotherapy for patients with relapsed or unresponsive Hodgkin lymphoma (HL) before a stem cell transplant. The authors concluded that this regimen was safe and effective for these patients. Some background Chemotherapy, followed by a stem cell transplant (SCT), remains the standard of...
Read MoreAsciminib as a treatment option for patients with chronic myeloid leukemia after kinase inhibitor failure
In a nutshell This study aimed to investigate if asciminib was effective in patients with chronic myeloid leukemia who had resistance or unacceptable side effects to other tyrosine kinase inhibitors. This study concluded that asciminib showed promise in these patients. Some background Asciminib is a...
Read MoreHow effective is long-term brentuximab vedotin treatment for patients with recurrent or non-responding Hodgkin’s lymphoma?
In a nutshell This study evaluated long-term treatment with brentuximab vedotin (Adcetris) for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study concluded that this treatment had a long-term benefit for some patients. Some background Most patients with HL respond well to initial treatment....
Read MoreEvaluating isatuximab for patients with recurrent or non-responding multiple myeloma
In a nutshell This study examined the effectiveness and safety of isatuximab plus PD (pomalidomide, dexamethasone) for patients with multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that isatuximab was well-tolerated and significantly improved survival outcomes for these patients. Some...
Read MoreEvaluating pembrolizumab for patients with primary mediastinal large B-cell lymphoma that has come back or stopped responding to treatment
In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with primary mediastinal large B-cell lymphoma (PMBCL) that has come back or stopped responding to treatment. This study concluded that pembrolizumab was safe and effective for these patients. Some background PMBCL is one rare and aggressive type...
Read MoreIs tislelizumab safe and effective for patients with relapsed or refractory classical Hodgkin’s lymphoma?
In a nutshell This study examined how effective and safe tislelizumab (BGB-A317) is for patients with relapsed or refractory classical Hodgkin's lymphoma (cHL). The authors concluded that most patients responded to tislelizumab but also experienced side effects. Some background cHL is often treated with chemotherapy or stem cell...
Read MoreEvaluating combination CAR-T cell therapy for recurrent or treatment-resistant multiple myeloma
In a nutshell This study evaluated the safety and effectiveness of combining two T-cell therapies for multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that this treatment showed promising effectiveness for these patients. Some background Treatment for patients with MM that has come back (relapsed)...
Read MoreLooking for patients with relapsed or unresponsive multiple myeloma to try allogeneic CAR-T cell therapy
In a nutshell This trial is evaluating the safety and effectiveness of allogeneic CAR-T cell therapy (ALLO-715) in patients with multiple myeloma (MM) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This trial is recruiting in Denver, CO. The details Chimeric...
Read MoreEvaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia
In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...
Read More
